Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Acrinova AB (publ) in connection with its uplisting to Nasdaq Stockholm
Mandate

Vinge advises Acrinova AB (publ) in connection with its uplisting to Nasdaq Stockholm

December 16, 2022 Capital Markets and Public M&A Corporate Tax

Vinge has advised Acrinova AB (publ) (“Acrinova” or the “Company”) in connection with the Company’s uplisting to Nasdaq Stockholm. The prospectus was published on 9 December 2022 and trading on Nasdaq Stockholm commenced on 16 December 2022.

Acrinova is a real estate group with a focus on southern Sweden and on commercial properties. The Company offers comprehensive services as owner, manager and developer of real estate. Acrinova has its headquarter in Malmö, Sweden. The Company is uplisting from Nasdaq First North Premier Growth Market, where the Company's shares have been listed since 2019.

Vinge’s team has primarily consisted of Linnéa Sellström, Emma Brolund, Lorin Arabi and Michaela Ådén (Capital Markets and Public M&A), as well as Victor Ericsson, Emelie Svanberg and Maja Prahl (Corporate Tax).

 

Related

Vinge advises Spetses Investments and Bacara Holdings on the public offer for IRRAS

 A bid consortium, acting through IR Holding Bidco Inc, has announced and completed a public offer to the shareholders of IRRAS AB (publ). The consortium included, among others, IRRAS’ two largest shareholders, Spetses Investments Ltd and Bacara Holdings Limited, both advised by Vinge.
October 03, 2023

Vinge advises SAGA Diagnostics AB on convertible note issue

 SAGA Diagnostics AB, a cancer diagnostics and disease monitoring company, has carried out a convertible note issue of approximately SEK 144 million. Vinge advised SAGA Diagnostics in connection with the transaction.
September 28, 2023

Vinge advises Repligen Corporation in connection with the acquisition of Metenova

 Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).
September 27, 2023